# STAT2

## Overview
The STAT2 gene encodes the signal transducer and activator of transcription 2 (STAT2) protein, a pivotal component of the JAK-STAT signaling pathway, particularly in the context of type I and III interferon responses. STAT2 is a transcription factor that plays a crucial role in mediating antiviral defense mechanisms by forming part of the interferon-stimulated gene factor 3 (ISGF3) complex, alongside STAT1 and IRF9. This complex translocates to the nucleus to regulate the expression of interferon-stimulated genes (ISGs), which are essential for innate and adaptive immune responses (Duncan2021Human; Blaszczyk2016The). The STAT2 protein is characterized by several structural domains, including a coiled-coil domain, DNA-binding domain, and SH2 domain, which facilitate its interactions and functional activities within the cell (Wang2020Structural). Mutations in the STAT2 gene can lead to significant clinical implications, such as increased susceptibility to viral infections and type I interferonopathies, underscoring its critical role in immune regulation (Duncan2021Human; Zhu2023Type).

## Structure
STAT2 is a protein involved in the interferon signaling pathway, characterized by several distinct structural domains. The primary structure of STAT2 includes a coiled-coil domain (CCD), a DNA-binding domain (DBD), a linker domain (LD), and an SH2 domain, which are packed sequentially (Wang2020Structural). The SH2 domain is crucial for interaction with phosphotyrosine residues, playing a significant role in the protein's function (Qureshi1996Function).

The secondary structure of STAT2 involves the formation of helices and beta strands, particularly in the transactivation domain (TAD), which wraps around the TAZ1 domain of CBP/p300, forming a stable, folded structure upon binding (Wojciak2009Structural). The TAD is intrinsically unstructured in isolation but undergoes structural changes upon interaction with coactivators (Wojciak2009Structural).

In terms of tertiary structure, the STAT2 protein assumes an elongated fold similar to other STAT proteins, with specific domains contributing to its overall architecture (Wang2020Structural). The quaternary structure involves the formation of complexes with other proteins, such as STAT1 and IRF9, to mediate gene expression (Qureshi1996Function).

Post-translational modifications, particularly phosphorylation at tyrosine 690, are critical for STAT2's activation and function (Qureshi1996Function). These modifications facilitate interactions with other proteins and are essential for its role in the interferon signaling pathway.

## Function
STAT2 is a critical component of the JAK-STAT signaling pathway, particularly in response to type I and III interferons (IFN-I/III). It forms part of the interferon-stimulated gene factor 3 (ISGF3) complex, which includes STAT1 and IRF9. This complex translocates to the nucleus to bind to interferon-stimulated response elements (ISRE) in the promoters of hundreds of interferon-stimulated genes (ISGs), playing a crucial role in antiviral responses (Duncan2021Human; Lee2020Stat2).

STAT2 is activated by tyrosine phosphorylation through receptor-associated kinases JAK1 and TYK2. This phosphorylation facilitates its dimerization with STAT1 and interaction with IRF9, forming the ISGF3 complex. The complex then translocates to the nucleus to activate transcription of ISGs, which are involved in antiviral responses and other immune functions (Blaszczyk2016The; Lee2020Stat2).

In addition to its role in the ISGF3 complex, STAT2 can form alternative complexes, such as STAT2/IRF9, which can activate a similar pool of genes as ISGF3. This highlights its role in diverse IFN-I signaling pathways, allowing for the transcription of a wide range of genes related to innate and adaptive immunity (Blaszczyk2016The).

## Clinical Significance
Mutations in the STAT2 gene can lead to significant clinical consequences, primarily affecting the immune system's ability to respond to viral infections. Autosomal recessive STAT2 deficiency results in increased susceptibility to severe and recurrent viral infections due to inadequate type I and III interferon activity. Individuals with this deficiency are particularly vulnerable to diseases caused by live-attenuated viral vaccines, such as measles, mumps, and rubella (MMR), and varicella zoster virus (vVZV) (Duncan2021Human). The deficiency impairs type I interferon signaling, specifically affecting IFN-α-induced responses, while IFN-γ responses remain unaffected (Moens2017A).

STAT2 mutations can also lead to type I interferonopathy, a condition characterized by an overactive interferon response. For instance, the homozygous missense mutation at the STAT2-R148 residue causes severe type I interferonopathy, marked by excessive IFN-I activity and associated with neurological and multisystem disease (Duncan2021Human). Another mutation, p.(A219V), disrupts the interaction with USP18, leading to prolonged activation of interferon-stimulated genes and sustained STAT2 phosphorylation, contributing to type I interferonopathy (Zhu2023Type). These mutations highlight the critical role of STAT2 in regulating immune responses and maintaining immune homeostasis.

## Interactions
STAT2 is a key component in the interferon signaling pathway, forming part of the ISGF3 complex with STAT1 and IRF9. This complex binds to interferon-stimulated response elements (ISRE) on DNA to regulate gene expression (Steen2012The; Blaszczyk2016The). STAT2 interacts with the IFNAR2c subunit of the interferon-alpha receptor, which is crucial for its activation and the subsequent activation of STAT1. The N-terminal domain of STAT2 is important for this interaction (Li1997Functional; Steen2012The).

STAT2 also forms heterodimers with STAT1 and STAT3, although STAT3 binds less effectively. These interactions are essential for the formation of active signaling complexes (Stancato1996Preassociation; Steen2012The). The coiled-coil domain of STAT2 is critical for its interaction with the p48 subunit of the ISGF3 complex, which is necessary for binding to ISRE (Shuai2000Modulation).

In addition to its role in forming the ISGF3 complex, STAT2 interacts with various transcriptional co-activators, such as p300/CBP and GCN5, which are recruited to facilitate gene transcription (Blaszczyk2016The). STAT2's interactions with these proteins and its role in the JAK/STAT pathway highlight its importance in mediating interferon responses and antiviral defense mechanisms (Steen2012The).


## References


[1. (Wojciak2009Structural) Jonathan M Wojciak, Maria A Martinez-Yamout, H Jane Dyson, and Peter E Wright. Structural basis for recruitment of cbp/p300 coactivators by stat1 and stat2 transactivation domains. The EMBO Journal, 28(7):948–958, February 2009. URL: http://dx.doi.org/10.1038/emboj.2009.30, doi:10.1038/emboj.2009.30. This article has 145 citations.](https://doi.org/10.1038/emboj.2009.30)

[2. (Zhu2023Type) Gaofeng Zhu, Mihaly Badonyi, Lina Franklin, Luis Seabra, Gillian I. Rice, Anne-Boland-Auge, Jean-François Deleuze, Salima El-Chehadeh, Mathieu Anheim, Anne de Saint-Martin, Sandra Pellegrini, Joseph A. Marsh, Yanick J. Crow, and Marie-Therese El-Daher. Type i interferonopathy due to a homozygous loss-of-inhibitory function mutation in stat2. Journal of Clinical Immunology, 43(4):808–818, February 2023. URL: http://dx.doi.org/10.1007/s10875-023-01445-3, doi:10.1007/s10875-023-01445-3. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10875-023-01445-3)

[3. (Steen2012The) Håkan C. Steen and Ana M. Gamero. The role of signal transducer and activator of transcription-2 in the interferon response. Journal of Interferon &amp; Cytokine Research, 32(3):103–110, March 2012. URL: http://dx.doi.org/10.1089/jir.2011.0099, doi:10.1089/jir.2011.0099. This article has 20 citations.](https://doi.org/10.1089/jir.2011.0099)

[4. (Lee2020Stat2) Cheol-Jung Lee, Hyun-Jung An, Eun Suh Cho, Han Chang Kang, Joo Young Lee, Hye Suk Lee, and Yong-Yeon Cho. Stat2 stability regulation: an intersection between immunity and carcinogenesis. Experimental &amp; Molecular Medicine, 52(9):1526–1536, September 2020. URL: http://dx.doi.org/10.1038/s12276-020-00506-6, doi:10.1038/s12276-020-00506-6. This article has 36 citations.](https://doi.org/10.1038/s12276-020-00506-6)

[5. (Wang2020Structural) Boxiao Wang, Stephanie Thurmond, Kang Zhou, Maria T. Sánchez-Aparicio, Jian Fang, Jiuwei Lu, Linfeng Gao, Wendan Ren, Yanxiang Cui, Ethan C. Veit, HeaJin Hong, Matthew J. Evans, Seán E. O’Leary, Adolfo García-Sastre, Z. Hong Zhou, Rong Hai, and Jikui Song. Structural basis for stat2 suppression by flavivirus ns5. Nature Structural &amp; Molecular Biology, 27(10):875–885, August 2020. URL: http://dx.doi.org/10.1038/s41594-020-0472-y, doi:10.1038/s41594-020-0472-y. This article has 48 citations.](https://doi.org/10.1038/s41594-020-0472-y)

[6. (Shuai2000Modulation) K Shuai. Modulation of stat signaling by stat-interacting proteins. Oncogene, 19(21):2638–2644, May 2000. URL: http://dx.doi.org/10.1038/sj.onc.1203522, doi:10.1038/sj.onc.1203522. This article has 283 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1203522)

[7. (Li1997Functional) Xiaoxia Li, Stewart Leung, Ian M. Kerr, and George R. Stark. Functional subdomains of stat2 required for preassociation with the alpha interferon receptor and for signaling. Molecular and Cellular Biology, 17(4):2048–2056, April 1997. URL: http://dx.doi.org/10.1128/MCB.17.4.2048, doi:10.1128/mcb.17.4.2048. This article has 269 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.17.4.2048)

[8. (Qureshi1996Function) Sajjad A. Qureshi, Stewart Leung, Ian M. Kerr, George R. Stark, and James E. Darnell. Function of stat2 protein in transcriptional activation by alpha interferon. Molecular and Cellular Biology, 16(1):288–293, January 1996. URL: http://dx.doi.org/10.1128/mcb.16.1.288, doi:10.1128/mcb.16.1.288. This article has 142 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.1.288)

[9. (Moens2017A) Leen Moens, Lien Van Eyck, Dirk Jochmans, Tania Mitera, Glynis Frans, Xavier Bossuyt, Patrick Matthys, Johan Neyts, Michael Ciancanelli, Shen-Ying Zhang, Rik Gijsbers, Jean-Laurent Casanova, Stephanie Boisson-Dupuis, Isabelle Meyts, and Adrian Liston. A novel kindred with inherited stat2 deficiency and severe viral illness. Journal of Allergy and Clinical Immunology, 139(6):1995-1997.e9, June 2017. URL: http://dx.doi.org/10.1016/j.jaci.2016.10.033, doi:10.1016/j.jaci.2016.10.033. This article has 69 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.jaci.2016.10.033)

[10. (Duncan2021Human) Christopher James Arthur Duncan and Sophie Hambleton. Human disease phenotypes associated with loss and gain of function mutations in stat2: viral susceptibility and type i interferonopathy. Journal of Clinical Immunology, 41(7):1446–1456, August 2021. URL: http://dx.doi.org/10.1007/s10875-021-01118-z, doi:10.1007/s10875-021-01118-z. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10875-021-01118-z)

[11. (Stancato1996Preassociation) Louis F. Stancato, Michael David, Christin Carter-Su, Andrew C. Larner, and William B. Pratt. Preassociation of stat1 with stat2 and stat3 in separate signalling complexes prior to cytokine stimulation. Journal of Biological Chemistry, 271(8):4134–4137, February 1996. URL: http://dx.doi.org/10.1074/JBC.271.8.4134, doi:10.1074/jbc.271.8.4134. This article has 192 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.271.8.4134)

[12. (Blaszczyk2016The) Katarzyna Blaszczyk, Hanna Nowicka, Kaja Kostyrko, Aleksandra Antonczyk, Joanna Wesoly, and Hans A.R. Bluyssen. The unique role of stat2 in constitutive and ifn-induced transcription and antiviral responses. Cytokine &amp; Growth Factor Reviews, 29:71–81, June 2016. URL: http://dx.doi.org/10.1016/j.cytogfr.2016.02.010, doi:10.1016/j.cytogfr.2016.02.010. This article has 106 citations.](https://doi.org/10.1016/j.cytogfr.2016.02.010)